Fintel reports that on November 7, 2024, Baird upgraded their outlook for McKesson (NYSE:MCK) from Neutral to Outperform. ...
McKesson Corporation MCK witnessed strong momentum ... The second segment offers enterprise-wide clinical, patient care, ...
The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...